Levetiracetam use in the critical care setting
Intravenous (IV) levetiracetam (LEV) is currently approved as an alternative or replacement therapy for patients unable to take the oral form of this antiepileptic drug (AED). The oral form has Food and Drug Administration (FDA) indications for adjunctive therapy in the treatment of partial onset e...
Main Authors: | Jerzy P Szaflarski, Jennifer Laurel DeWolfe |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2013-08-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fneur.2013.00121/full |
Similar Items
-
Intravenous levetiracetam in critically ill children
by: Faruk Incecik, et al.
Published: (2016-01-01) -
Levetiracetam versus phenytoin in children with status epilepticus
by: Gowhar Wani, et al.
Published: (2019-01-01) -
Clinical Pharmacology and Pharmacokinetics of Levetiracetam
by: Chanin Clark Wright, et al.
Published: (2013-12-01) -
Intravenous levetiracetam versus phenobarbital in children with status epilepticus or acute repetitive seizures
by: Yun-Jeong Lee, et al.
Published: (2016-01-01) -
Mechanisms of levetiracetam in the control of status epilepticus and epilepsy
by: Laxmikant S Deshpande, et al.
Published: (2014-01-01)